Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411466 | 0.81 | MEN1 (0.40) | KMT2ANPC1RAB9ABRD4MEN1 | |
| SCHEMBL23264682 | 0.79 | MEN1 (0.38) | KMT2ABRD4MEN1POLBPIK3CA | |
| SCHEMBL21411487 | 0.76 | MAT2A (0.45) | KMT2ABRD4MEN1POLB | |
| SCHEMBL243387 | 0.75 | KDM4E (0.45) | KMT2ANPC1RAB9AMEN1POLB | |
| SCHEMBL21411480 | 0.74 | ALDH1A1 (0.35) | KMT2ANPC1RAB9ABRD4MEN1 | |
| SCHEMBL15674574 | 0.73 | DHODH (0.47) | KMT2ANPC1RAB9AMEN1SQOR | |
| SCHEMBL21428642 | 0.72 | MAT2A (0.48) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL21411398 | 0.71 | MAT2A (0.51) | KMT2AMEN1 | |
| SCHEMBL25569932 | 0.70 | LMNA (0.43) | KMT2ANPC1RAB9AMEN1L3MBTL1 | |
| SCHEMBL245541 | 0.69 | CCR1 (0.46) | KMT2ANPC1RAB9AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | SERVIER PHARMACEUTICALS LLC (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | MAT2A, MAT2B, MAT1A | KMT2A 189/4885NPC1 3259/4885RAB9A 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.